Conditions: HIV Infections Cognition Disorders
Keywords: Acquired Immunodeficiency Syndrome AIDS-Related Complex
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 215
Healthy volunteers: no

Brief summary:
To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals.

Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients.

Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.

Detailed description:

Arms:
arm 1: Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months arm 2: Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months

Interventions: intervention 1: Peptide T intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: